The browser doesnot support javascript
Print Plan Forms | Help

Medication Safety Alerts

Potiga Discontinuation

7/05/2017

On July 5, 2017, GlaxoSmithKline announced their decision to discontinue Potiga® 50 mg, 200 mg, 300 mg and 400 mg tablets on June 30, 2017. This discontinuation is due to the limited usage of the medicine and not due to efficacy or safety reasons. As part of this discontinuation, GlaxoSmithKline issued a withdrawal of all lots of these products within expiry.

A complete list of the affected products is providedhere.

CVS Caremark Response: As a result of this issue, CVS Caremark will no longer be able to fill prescriptions for Potiga. Patients will need to obtain new prescriptions for a different medicine to treat their condition.

For more information about this issue, health care providers may contact GlaxoSmithKline at 1‑888-825-5249, Monday through Friday, 8:30 A.M through 5:30 P.M (ET) or visit https://us.gsk.com. You may also contact the U.S. Food and Drug Administration (FDA) consumer inquiry line at 1‑888-INFO-FDA (1-888-463-6332) or by accessing their Web site at www.fda.gov.

The CVS/caremark™ app lets you manage your prescription benefits on the go. Download it now:

CVS Health LogoCVS Pharmacy LogoCVS Minute Clinic LogoCVS Specialty LogoSilverscript LogoAccordant Logo

Copyright © 2018 CVS/caremark. All rights reserved| Terms and Conditions | Privacy Policy | Accessibility | Member Rights & Responsibilities